NCT00482521View on ClinicalTrials.gov

CC-4047 in Treating Patients With Advanced Solid Tumors That Did Not Respond to Treatment

PHASE1CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

March 31, 2007

Primary Completion Date

September 30, 2010

Study Completion Date

August 31, 2012

Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
DRUG

CC-4047

Oral CC-4047 once daily on days 1-21 followed by a 7-day recovery period. Cohorts of 3-6 patients receive escalating doses of CC-4047 until the maximum tolerated dose (MTD) is determined.

Trial Locations (2)

44195

Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland

44106-5065

Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Case Comprehensive Cancer Center

OTHER

NCT00482521 - CC-4047 in Treating Patients With Advanced Solid Tumors That Did Not Respond to Treatment | Biotech Hunter | Biotech Hunter